A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

NCT06055166 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

PARP Inhibitor for Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))

Sponsor

Chongqing University Cancer Hospital